ASX Announcements Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising. Keyword Search Year None202120202019 Date Title 29 November 2021 Results of Meeting 29 November 2021 CEO Presentation to 2021 Annual General Meeting 29 November 2021 Mesoblast Chairman Message to 2021 AGM 24 November 2021 MSB Q1 Financial Results and Operational Highlights 24 November 2021 First Quarter Results Presentation 24 November 2021 First Quarter Financial Results on Form 6-K 23 November 2021 Mesoblast Q1 Financial Results Webcast 22 November 2021 MSB and Oaktree Conclude Refinancing of Senior Debt Facility 22 November 2021 Proposed issue of securities - MSB 15 November 2021 AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes 29 October 2021 Annual Report to Shareholders 29 October 2021 Notice of Annual General Meeting and Proxy Form 29 October 2021 Appendix 4G and Corporate Governance Statement 29 October 2021 Appendix 4C Quarterly Activity Report 18 October 2021 Remestemcel-L Improves Survival in High-Risk Acute GvHD 14 October 2021 Notification of cessation of securities - MSB 14 October 2021 Notification regarding unquoted securities - MSB 07 October 2021 CHF Late Breaker Presentation at American Heart Association 31 August 2021 MSB Annual Financial Results and Operational Progress 31 August 2021 Annual Financial Results Presentation 31 August 2021 Preliminary Final Report including Appendix 4E 30 August 2021 Appendix 3G and 3H 30 August 2021 Mesoblast 2021 Full Year Financial Results Webcast 10 August 2021 Mesoblast Management Update 30 July 2021 Appendix 4C Quarterly Activity Report 29 July 2021 Release of Shares from Voluntary Escrow 19 July 2021 COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT 16 July 2021 COVID ARDS Trial Respiratory Outcomes Presented 16 July 2021 COVID ARDS Trial Results Presentation 14 July 2021 Appendix 3Y - Change of Director's Interest Notice 07 July 2021 Appendix 3G 01 July 2021 Mesoblast Update on Chronic Low Back Pain Program 03 June 2021 MSB Reports Q3 Financial Results and Operational Highlight 03 June 2021 Third Quarter Results Presentation 03 June 2021 Third Quarter Financial Results on Form 6-K 03 June 2021 Mesoblast Q3 Financial Results Webcast 25 May 2021 Remestemcel-L for COPD Published in Respiratory Research 30 April 2021 COVID ARDS Trial Topline 60-Day Results 30 April 2021 Appendix 4C Quarterly Activity Report 30 April 2021 Mesoblast Corporate Update Webcast 06 April 2021 Director's Interest Notice - Appendix 3X 31 March 2021 Mesoblast Operational Highlights and Upcoming Milestones 29 March 2021 Director Appointment/Resignation 29 March 2021 Director Appointment/Resignation 15 March 2021 Prospectus for Warrants in Connection with US$110M Raise 09 March 2021 MSB Closes US$110M Raise Led By US Strategic Investor Group 09 March 2021 Cleansing Notice and Appendix 2A 03 March 2021 Cleansing Notice and Appendix 2A 02 March 2021 Proposed issue of Securities - MSB 02 March 2021 Mesoblast Raises US$110M Led By US Strategic Investor Group 26 February 2021 Half Year Report and Accounts (including Appendix 4D) 26 February 2021 Trading Halt 17 February 2021 Remestemcel-L for COVID-19 MIS-C published in Pediatrics 11 February 2021 Mesoblast Phase 3 Chronic Low Back Pain Results 11 February 2021 Mesoblast Corporate Update Webcast 29 January 2021 Appendix 4C Quarterly Activity Report 12 January 2021 CHF Phase 3 Trial Results Presented at Investor Conference 12 January 2021 Mesoblast Healthcare Conference Investor Presentation 11 January 2021 Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
